Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

01-08-2012 | Original Paper

Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice

Auteurs: Matthew Siegel, Amy A. Beaulieu

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 8/2012

Abstract

This paper presents a systematic review, rating and synthesis of the empirical evidence for the use of psychotropic medications in children with autism spectrum disorders (ASD). Thirty-three randomized controlled trials (RCTs) published in peer-reviewed journals qualified for inclusion and were coded and analyzed using a systematic evaluative method specific to autism research (Reichow et al. in Journal of Autism and Developmental Disorders 38:1311–1319, 2008). Results are presented by agent and primary target symptom(s). The findings suggest established evidence for relatively few agents, with preliminary and promising evidence for a larger group. Challenges and opportunities in the developing field of ASD psychopharmacology are identified, and recommendations for further research are provided.

vorige artikel Diagnostic Yield of Chromosomal Microarray Analysis in an Autism Primary Care Practice: Which Guidelines to Implement?

volgende artikel Audiovisual Speech Perception and Eye Gaze Behavior of Adults with Asperger Syndrome

Akhondzadeh, S., Erfani, S., Mohammadi, M. R., Tehrani-Doost, M., Amini, H., Gudarzi, S. S., et al. (2004). Cyproheptadine in the treatment of autistic disorder: A double-blind placebo-controlled trial. Journal of Clinical Pharmacy & Therapeutics, 29(2), 145–150. CrossRef

Akhondzadeh, S., Fallah, J., Mohammadi, M. R., Imani, R., Mohammadi, M., Salehi, B., et al. (2010). Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 32–36. PubMedCrossRef

Aman, M. G., Singh, N. N., & Stewart, A. W. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiencies, 89, 485–491.

Aman, M. G., Lam, K. S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527–534. PubMedCrossRef

Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141(10), 195–202.

Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19(2), 227–239. PubMedCrossRef

Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205. PubMedCrossRef

Beaulieu, A., Tweed, L., & Connolly, N. (2009). Interventions for autism spectrum disorders: State of the evidence. Augusta, Maine: Muskie School of Public Service and Maine Department of Health and Human Services.

Beduin, A. S., & de Haan, L. (2010). Off-label second generation antipsychotics for impulse regulation disorders: A review. Psychopharmacology Bulletin, 43(3), 45–81.

Belsito, L., Law, P., Kirk, K., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized double-blind placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175–181. PubMedCrossRef

Campbell, M., Anderson, L. T., Small, A. M., Locascio, J. J., Lynch, N. S., & Choroco, M. C. (1990). Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacology Bulletin, 26(1), 130–135. PubMed

Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32(6), 1283–1291. PubMedCrossRef

Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1(2), 83–88.

Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the Social Responsiveness Scale with the Autism Diagnostic Interview-Revised. Journal of Autism and Developmental Disorders, 33(4), 427–433. PubMedCrossRef

Feldman, H. M., Kolmen, B. K., & Gonzaga, A. M. (1999). Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 587–593. PubMedCrossRef

Freeman, J. B., Choate-Summers, M. L., Garcia, A. M., Moore, P. S., Sapyta, J. J., Khanna, M. S., et al. (2009). The pediatric obsessive-compulsive disorder treatment study II: Rationale, design and methods. Child and Adolescent Psychiatry and Mental Health, 3(1), 4. PubMedCrossRef

Gordon, C. T., State, R. C., Nelson, J. F., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, deipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447. PubMedCrossRef

Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255. PubMedCrossRef

Handen, B., Sahl, R., & Harden, A. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308. PubMedCrossRef

Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682–692. PubMedCrossRef

Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005a). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology: Official Publication of The American College of Neuropsychopharmacology, 30(3), 582–589. CrossRef

Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2005b). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. The International Journal of Neuropsychopharmacology: Official Scientific Journal of The Collegium Internationale Neuropsychopharmacologicum (CINP), 9(2), 209–213.

Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., et al. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child & Adolescent Psychopharmacology, 16, 541–548. CrossRef

Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Russoff, J., et al. (2010). Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990–998. PubMedCrossRef

Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327. PubMedCrossRef

Johnson, C. P., & Myers, S. M. (2007). Identification and evaluation of children with autism spectrum disorders. Pediatrics, 120(5), 1183–1215. PubMedCrossRef

King, B. H., & Bostic, J. Q. (2006). An update on pharmacologic treatments for autism spectrum disorders. Child and Adolescent Psychiatry Clinics of North America, 15(1), 161–175. CrossRef

King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. (2001). Double-blind placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 658–665. PubMedCrossRef

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahil, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry, 66(6), 583–590. PubMedCrossRef

Kolmen, B. K., Feldman, H. M., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: A double-blind placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(2), 223–231. PubMedCrossRef

Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159–174. PubMedCrossRef

LeCavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101–1114. PubMedCrossRef

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. PubMedCrossRef

McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148. PubMedCrossRef

Mcpheeters, M. L., Warren, Z., Sathe, N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127, e1312. PubMedCrossRef

Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry, 17(1), 1–8. PubMedCrossRef

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540. PubMedCrossRef

Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25(3), 283–294. PubMedCrossRef

Reichow, B., Volkmar, F. R., & Cicchetti, D. V. (2008). Development of the evaluative method for evaluating and determining evidence-based practices in autism. Journal of Autism and Developmental Disorders, 38, 1311–1319. PubMedCrossRef

Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 4, 440–444. CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321. CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005). A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Archives of General Psychiatry, 62, 1266–1274. CrossRef

Scahill, L., Riddle, M., & McSwiggin-Hardin, M. (1997). Children’s yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 844–852. PubMedCrossRef

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef

Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 21(6), 363–367. PubMedCrossRef

Willemsen-Swinkels, S. H., Buitelaar, J. K., Weijnen, F. G., & van Engeland, H. (1995). Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research, 58(3), 203–215. PubMedCrossRef

Wong, H. H. L., & Smith, R. G. (2006). Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. Journal of Autism and Developmental Disorders, 36, 901–909. PubMedCrossRef

Titel: Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice
Auteurs: Matthew Siegel
Amy A. Beaulieu
Publicatiedatum: 01-08-2012
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 8/2012
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-011-1399-2

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2012

Goal-Directed and Goal-Less Imitation in Autism Spectrum Disorder

Limitations of Meta-Analyses

Erratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes

Training Community Mental Health Therapists to Deliver a Package of Evidence-Based Practice Strategies for School-Age Children with Autism Spectrum Disorders: A Pilot Study

Utility of the Social Communication Questionnaire-Current and Social Responsiveness Scale as Teacher-Report Screening Tools for Autism Spectrum Disorders

A. Stalker: The One and Only Sam: A Story Explaining Idioms for Children with Asperger Syndrome and Other Communication Difficulties